Mango Sciences, a data and AI company based in Boston, US, and Bengaluru, India, has announced a strategic partnership with ImmunoAdoptive Cell Therapy (ImmunoACT), a Mumbai, India-based cell and gene therapy development company, to broaden access and affordability for ImmunoACT’s NexCAR19™ chimeric antigen receptor T-cell (CAR-T) therapy for leukaemia and lymphoma patients.
This collaboration will enable patients to access NexCAR19™ with 0% interest EMI plans up to ₹10 lakhs to cover treatment costs. Additionally, clinically eligible patients may qualify for a value-based offering of up to ₹10 lakhs. NexCAR19™ is described as a pioneering product that offers access to this advanced therapy in India at an accessible price, with this partnership designed to expand its reach to more patients. The Mango Sciences plan benefits will initially be available at select healthcare facilities for patients receiving NexCAR19™.
Dr. Mohit Misra, Founder and CEO of Mango Sciences, stated, “We are excited to bring our Value-Based offerings to CAR-T – a global first. We aim to utilise data science and technology to ensure patients can access the latest innovations in oncology. Together with ImmunoACT, we are committed to improving access to innovative treatments, such as CAR-T, to improve the paradigm of cancer outcomes.”
Dr. Rahul Purwar, Founder of ImmunoACT, commented, “We are delighted to partner with Mango to improve access and affordability for patients who need NexCAR19. The programs shall significantly help patients to afford our therapy, and are outcome-based, demonstrating our conviction and evidence of NexCAR19’s efficacy and safety.”
Mango Sciences is a healthcare data and AI technology company focused on enhancing patient care through advanced data analytics. Founded by professionals with experience in healthcare, life sciences, and data analytics, the company aims to improve patient representation and access to comprehensive healthcare. Its Value-Based offering program seeks to alleviate financial burdens for cancer patients paying out-of-pocket and enable pharmaceutical innovators to scale product access sustainably.
ImmunoACT is a cell and gene therapy company, incubated at IIT Bombay, dedicated to providing accessible autologous CAR-T cell therapies for cancer. The company received Market Authorization from the Central Drugs Standard Control Organization (CDSCO) in October 2023 for its flagship product, Actalycabtagene autoleucel (NexCAR19™). ImmunoACT is expanding its pipeline from blood cancers to solid tumors and autoimmune disorders, aiming to offer medical professionals effective cancer therapy alternatives to traditional treatments.
